Characteristics and Treatment Response of Patients with HIV Associated Kaposi's Sarcoma in Central Kenya

被引:1
|
作者
McLigeyo, Angela [1 ]
Owuor, Kevin [1 ]
Ng'ang'a, Evelyne [1 ]
Mwangi, Jonathan [2 ]
Wekesa, Paul [1 ]
机构
[1] Ctr Hlth Solut Kenya, CVS Plaza,4th Floor,Kasuku Rd,Off Lenana Rd, Nairobi, Kenya
[2] Ctr Dis Control & Prevent CDC, Div Global HIV & TB, Nairobi, Kenya
来源
HIV AIDS-RESEARCH AND PALLIATIVE CARE | 2022年 / 14卷
关键词
HIV; Kaposi's sarcoma; characteristics; treatment; response; adults; ACTIVE ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; HERPESVIRUS; MEN; HUMAN-HERPESVIRUS-8; PREVALENCE; OUTCOMES; PATTERN; CANCER; HAART;
D O I
10.2147/HIV.S359278
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Kaposi's sarcoma (KS) is the most common HIV-associated malignancy in Sub Saharan Africa. In 2018, it was the 7th most common cancer and the 10th most common cause of cancer death in Kenya. This study aimed to describe the baseline and clinical characteristics and treatment response observed following combined antiretroviral treatment (ART) and chemotherapy in KS patients. Methods: This was a descriptive analysis of patients aged >= 15 years treated for KS and HIV at 11 treatment hubs in Central Kenya between 2011 and 2014. Data on baseline and clinical characteristics, ART and chemotherapy regimens as well as treatment responses were collected from patient files and KS registers. Results: A total of 95 patients presenting with clinically suspected KS with no history of prior treatment with chemotherapy were reviewed. All had histological diagnostic samples taken with 67 (71%) having confirmed KS. All were on ART, either newly initiated or continuing on ART, and 63 of the 67 (94.0%) confirmed to have KS received chemotherapy. Among the 67 patients with confirmed KS, mean age was 37.2 years (+/- 13.2) and 40 (59.7%) were male. More than 80% had normal baseline and follow-up BMI, and 34 (50.7%) were on a TDF-based regimen, 52 (77.6%) were treated with the Adriamycin, bleomycin and vinblastine protocol, and 55 (82.1%) had KS diagnosis before HIV diagnosis. All 67 patients had mucocutaneous lesions. Complete, partial response and stable disease occurred in 27 (40.3%), 10 (14.9%) and 7 (10.4%), respectively, 11 (16.4%) defaulted care during treatment, six patients died during treatment, four patients died before treatment while two patients had progressive disease during chemotherapy. Conclusion: The diagnosis of KS preceded HIV in the majority of cases reviewed, with histology helpful to reduce misdiagnosis. Patients generally complied with their chemotherapy, with overall good response rate for this intervention implemented at primary health-care facilities.
引用
收藏
页码:207 / 215
页数:9
相关论文
共 50 条
  • [21] Radiation Therapy in the Treatment of HIV-related Kaposi's Sarcoma
    Donato, Vittorio
    Guarnaccia, Roberta
    Dognini, Jessica
    De Pascalis, Giovanni
    Caruso, Cristina
    Bellagamba, Rita
    Morrone, Aldo
    ANTICANCER RESEARCH, 2013, 33 (05) : 2153 - 2157
  • [22] Kaposi's Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition
    Palich, Romain
    Makinson, Alain
    Veyri, Marianne
    Guihot, Amelie
    Valantin, Marc-Antoine
    Bregigeon-Ronot, Sylvie
    Poizot-Martin, Isabelle
    Solas, Caroline
    Grabar, Sophie
    Martin-Blondel, Guillaume
    Spano, Jean-Philippe
    CANCERS, 2021, 13 (22)
  • [23] High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi's sarcoma
    Ridolfo, AL
    Santambrogio, S
    Mainini, F
    Vago, L
    Gervasoni, C
    Gori, A
    Parravicini, C
    Monforte, AA
    Galli, M
    AIDS, 1996, 10 (02) : 181 - 185
  • [24] Association of haptoglobin phenotypes with the development of Kaposi's sarcoma in HIV patients
    Speeckaert, Reinhart
    Colebunders, Bob
    Boelaert, Johan R.
    Brochez, Lieve
    Van Acker, Jos
    Van Wanzeele, Filip
    Hemmer, Robert
    Speeckaert, Marijn M.
    Verhofstede, Chris
    De Buyzere, Marc
    Arendt, Vic
    Plum, Jean
    Delanghe, Joris R.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2011, 303 (10) : 763 - 769
  • [25] Association of haptoglobin phenotypes with the development of Kaposi’s sarcoma in HIV patients
    Reinhart Speeckaert
    Bob Colebunders
    Johan R. Boelaert
    Lieve Brochez
    Jos Van Acker
    Filip Van Wanzeele
    Robert Hemmer
    Marijn M. Speeckaert
    Chris Verhofstede
    Marc De Buyzere
    Vic Arendt
    Jean Plum
    Joris R. Delanghe
    Archives of Dermatological Research, 2011, 303 : 763 - 769
  • [26] Kaposi's sarcoma: A presenting sign of HIV
    Vaishnani, Jignesh B.
    Bosamiya, Sanjay S.
    Momin, Anjum M.
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2010, 76 (02): : 215
  • [27] Demographic, clinical and treatment characteristics of patients with Kaposi's sarcoma: A single-center study
    Salman, Andac
    Ozgen, Zuleyha
    MARMARA MEDICAL JOURNAL, 2019, 32 (02): : 86 - 89
  • [28] Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection
    Unemori, Patrick
    Leslie, Kieron S.
    Hunt, Peter W.
    Sinclair, Elizabeth
    Epling, Lorrie
    Mitsuyasu, Ronald
    Effros, Rita B.
    Dock, Jeffrey
    Dollard, Sheila G.
    Deeks, Steven G.
    Martin, Jeffrey N.
    Maurer, Toby A.
    AIDS, 2013, 27 (11) : 1735 - 1742
  • [29] Negative HHV-8 immunoreactivity in HIV associated Kaposi's sarcoma
    Manuraj, Singh
    Steve, Morris
    Heinz, Kutzner
    Alistair, Robson
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (07) : 626 - 628
  • [30] Kaposi's sarcoma-associated herpesvirus and Kaposi's sarcoma
    Gruffat, H
    Sergeant, A
    Manet, E
    MICROBES AND INFECTION, 2000, 2 (06) : 671 - 680